Lumida
/INSM
⌘K
Insmed Inc

Insmed Inc

INSM
$129.41USD↑+1.67%+2.13 today

MARKET CAP

28.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$127 – $130

52W RANGE

$90
$213

AI Summary

Stalk
Buy NowMedium

INSM exhibits a medium-term bullish posture driven by a Bullish Pivot Point and successive Higher Highs & Higher Lows patterns, with price trading above rising 9/20 EMAs. Short-term conditions favor immediate participation as price resolves consolidation into a breakout zone. Execution should occur now, targeting continuation participation while remaining mindful of the long-term downtrend signaled by a declining 200 DMA.

  • ↑Q2 Brinsupri revenue $309.2M up 49% sequential affirms strong demand
  • ↑Raised full-year 2026 Brinsupri guidance to $1.25–$1.4B on robust uptake
  • ↓Negative earnings yield and low book-to-price ratio suggest overvaluation
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company focused on developing innovative therapies for serious respiratory diseases. The company has a portfolio that includes Brinsupri, a recently launched treatment for bronchiectasis, alongside pipeline assets aimed at addressing unmet medical needs in chronic conditions such as pulmonary hypertension and inflammatory diseases. Insmed is leveraging its expertise in this niche market to solidify its position, aiming for significant growth driven by strong product demand and rising sales forecasts.

Bull says

  • ↑Q2 Brinsupri revenue $309.2M up 49% sequential affirms strong demand
  • ↑Raised full-year 2026 Brinsupri guidance to $1.25–$1.4B on robust uptake
  • ↑~7,000 new Brinsupri patient starts in Q2 drive market penetration
  • ↑Cash reserves of ~$1.2B support operations until 2027 cash-flow positivity
  • ↑TPIP pipeline peak sales potential >$6B highlights significant growth runway
  • ↑High growth and positive analyst revisions factors bolster valuation

Bear says

  • ↓Negative earnings yield and low book-to-price ratio suggest overvaluation
  • ↓Weak profitability amid rising opex raises sustainability concerns
  • ↓High leverage heightens interest-rate sensitivity and refinancing risk
  • ↓Regulatory delays in markets like Japan could impede sales expansion
  • ↓Intense respiratory therapy competition may erode market share
  • ↓Valuation and leverage factor risks weigh on financial stability

Investment themes with INSM

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 03-05-2025bullish

Transcript signals

Bull points

  • In a world where ASPEN clears that hurdle and is statistically significant at either dose below 0.01, the physicians to a person have said this drug is going to fly off the shelf. They will proactively call their patients in. They will enthusiastically embrace the use of this drug.
  • I think you’re going to see a very rapid uptake in the use of this drug, not only because it’s the first ever approved medicine for this condition, but because the treatment burden of a once a day pill and the safety profile suggested by WILLOW and what we’ve seen in ASPEN so far is very positive.
  • the sheer appetite that we’ve seen at the different conferences in terms of medical education and responsiveness to the potential for a drug arriving to treat this disease is very significant.

Bear points

  • there is a general skepticism out there that we’ve encountered from people who say no one’s really been able to conquer the bronchiectasis market.
  • we feel pretty comfortable with this space. As you may know, I was on the SPAC that was involved in the MoonLake merger and acquisition, so I’ve been around HS for a while.
  • the probability of having those kinds of influences or aberrations in our study is extremely low.
Read full transcript analysis ›